Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

NCT02934529 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

673

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Irinotecan
DRUG: Folinic Acid
DRUG: 5-FU
DRUG: 5-FU
DRUG: Cetuximab
DRUG: Bevacizumab
DRUG: Capecitabine
DRUG: regorafenib
DRUG: Irinotecan 125mg
DRUG: Cetuximab wkly

Sponsor

Ludwig-Maximilians - University of Munich